Expression and Function of CD44 in Epithelial Ovarian Carcinoma

Sacks, Joelle D.; Barbolina, Maria V.

doi:10.3390/biom5043051

Cited by 49 publications

(40 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD44 is a glycoprotein receptor activated by hyaluronic acid, with role in cell to cell adhesion and recently described as a stem cell marker, reported positive in the majority of epithelial ovarian cancer and correlated with advance stage disease and unfavorable 5-year prognosis 23,24 . CD44 expressed focal positivity in all cases of LG carcinoma (100%) and had different patterns in HG carcinoma ( Figure 5).…”

Section: Resultsmentioning

confidence: 99%

High-grade versus low-grade serous carcinoma of the ovary – current differential diagnosis and perspectives

Popa¹,

COROBEA²,

Munteanu³

et al. 2018

Arch Balk Med Union

View full text Add to dashboard Cite

Comparaison entre les deux types de carcinome séreux de l'ovaire, à haut et à bas degré-diagnostic différentiel courant et perspectives Introduction. Le carcinome séreux est responsable de 47% de tous les cancers de l'ovaire. Parmi ces cas, 5% seulement sont représentés par un carcinome séreux à bas degré, le reste d'entre eux représentant un carcinome séreux à haut degré. Objectifs. Le but de cette étude est une approche observationnelle des différences et des similitudes entre les deux types de carcinome séreux de l'ovaire, qui doivent être considérés comme des formes différentes de cancer et traités avec précaution. Méthodes. Nous avons réalisé une étude rétrospective utilisant trois cas de carcinome séreux ovarien à haut degré et trois cas de carcinome séreux à bas degré ovarien, diagnostiqués à l'Hôpital Universitaire d'Urgence de Bucarest. Nous avons analysé l'âge des patients, les symptômes cliniques, les caractéristiques ABSTRACT Introduction. Serous carcinoma is responsible for 47% of all ovarian cancers, and from these cases, only 5% are represented by low-grade serous carcinoma, the rest of them accounting for high-grade serous carcinoma. Objective. The aim of this study is an observational approach of the differences and similarities of the two types of serous carcinoma of the ovary, that must be seen as different forms of cancer and rendered with care. Methods. We performed a retrospective study using three cases of ovarian high-grade serous carcinoma and three cases of ovarian low-grade serous carcinoma, diagnosed at the University Emergency Hospital Bucharest. We analyzed patients' age, clinical symptoms, macroscopic and microscopic features together with immunohistochemistry tests. Results. Mean age for HG carcinoma was 71.3 years old and for LG carcinoma 47.6 years old. Average tumor diameter was with 5.67 cm higher for LG carcinoma. The most encountered stage for HG tumors was pT2a and for LG tumors was pT1a. Mean value

show abstract

Section: Resultsmentioning

confidence: 99%

High-grade versus low-grade serous carcinoma of the ovary – current differential diagnosis and perspectives

Popa¹,

COROBEA²,

Munteanu³

et al. 2018

Arch Balk Med Union

View full text Add to dashboard Cite

show abstract

“…Analyses of ovarian cancer patient specimens further show that CD44 expression is associated with high-grade and advanced stage ovarian carcinoma 15. These evidences clearly pinpoint a critical role of CD44 in ovarian cancer progression and metastasis 16. This notion is buttressed by the observations that CD44-targeted antibodies or short hairpin RNAs inhibit ovarian cancer cell adhesion to mesothelial cells and peritoneal implantation 17, 18.…”

Section: Introductionmentioning

confidence: 98%

Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth

Zheng

Zhao

et al. 2017

Theranostics

View full text Add to dashboard Cite

CD44 and EpCAM play crucial roles in intraperitoneal ovarian cancer development. In this study, we developed an RNA-based bispecific CD44-EpCAM aptamer that is capable of blocking CD44 and EpCAM simultaneously by fusing single CD44 and EpCAM aptamers with a double stranded RNA adaptor. With the aid of a panel of ovarian cancer cell lines, we found that bispecific CD44-EpCAM aptamer was much more effective than either single CD44 or EpCAM aptamer in the ability to inhibit cell growth and to induce apoptosis. When these aptamers were tested in intraperitoneal ovarian cancer xenograft model, bispecific CD44-EpCAM aptamer suppressed intraperitoneal tumor outgrowth much more significantly than single CD44 and EpCAM aptamer either alone or in combination. The enhanced efficacy of bispecific CD44-EpCAM aptamer is most likely to be attributed to its increased circulation time over the single aptamers. Moreover, we showed that bispecific CD44-EpCAM aptamer exhibited no toxicity to the host and was unable to trigger innate immunogenicity. Our study suggests that bispecific CD44-EpCAM aptamer may represent a promising therapeutic agent against advanced ovarian cancer.

show abstract

“…CD44 protein belong to a class of cell adhesion receptors involved in a variety of cellular processes including the regulation of growth, survival, differentiation, and motility . CD44 has been reported to be involved in promoting tumor development, progression, and cancer stem cells and is linked to poor prognosis in several tumor indications like pancreas and breast cancer, hematologic malignancies, and hepatocellular carcinoma .…”

Section: Introductionmentioning

confidence: 99%

HnRNPM and CD44s expression affects tumor aggressiveness and predicts poor prognosis in breast cancer with axillary lymph node metastases

Sun

Liu

Zhu

et al. 2017

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

HnRNPM is an essential splicing factor and its expression is closely correlated with invasion and metastasis of tumor cells. The CD44 cell adhesion molecule is aberrantly expressed in many breast tumors and CD44 splice variants have been implicated in specific oncogenic signaling pathways. To investigate the clinical significance and biological function of hnRNPM, immunohistochemistry, quantitative, and semiquantitative polymerase chain reaction, lentiviral transfection system and transwell invasion assays were performed. We found that hnRNPM expression was significantly upregulated in breast cancer tissues compared with benign breast lesions. Although there was no significant correlation between hnRNPM and total CD44 protein or mRNA level, there was a negative correlation between hnRNPM and CD44v6. HnRNPM and CD44s expression showed positive correlation and in particular, they were dually expressed in breast cancer tissues. Interestingly, cancer stem cells marker, ALDH1 phenotype was positively associated with overexpression of CD44s or hnRNPM and negatively related to CD44v6. Patients with high hnRNPM tended to have higher levels of CD44s, shorter overall survival (OS) and higher rates of lymph node metastases (LNM). Remarkably, Kaplan-Meier and Cox regression analyses displayed that hnRNPM or CD44s was a poor prognostic factor for OS of patients with LNM. Upregulation of hnRNPM in MCF-7 cells caused a significant increase in cell invasion, and this effect may occur through the regulation of CD44s expression. In conclusion, overexpression of hnRNPM promotes breast cancer aggressiveness by regulating the level of CD44s, indicates a poor prognosis for patients with LNM, and has potential as therapeutic targets.

show abstract

Expression and Function of CD44 in Epithelial Ovarian Carcinoma

Cited by 49 publications

References 78 publications

High-grade versus low-grade serous carcinoma of the ovary – current differential diagnosis and perspectives

High-grade versus low-grade serous carcinoma of the ovary – current differential diagnosis and perspectives

Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth

HnRNPM and CD44s expression affects tumor aggressiveness and predicts poor prognosis in breast cancer with axillary lymph node metastases

Contact Info

Product

Resources

About